SUBSCRIBE
SUBSCRIBE
News   Deals

Ambrilia Biopharma Inc. Sells Prostate Cancer Drug Candidate to Kotinos Pharmaceuticals Inc. for up to $15 Million

July 17, 2009 | 
1 min read
Bookmark and Share

Reuters -- Small Canadian biotech company Ambrilia Biopharma Inc said it agreed to sell its experimental prostate cancer drug, PCK3145, to Kotinos Pharmaceuticals Inc.
Mergers & acquisitions Australia
MORE ON THIS TOPIC
A businessman hold a ladder, he tried to break through barriers to move forward
Earnings
Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera
November 4, 2025
 · 
5 min read
 · 
Annalee Armstrong
Money trap and business risks, insurance concept. Vector of greedy businessman running to the bait, another man trying stop him.
Mergers & acquisitions
Novo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid
November 4, 2025
 · 
1 min read
 · 
Annalee Armstrong
Business negotiation and cooperation vector concept. Symbol of a deal, handshake, success. Minimal design eps10 illustration.
Immunology and inflammation
Neurocrine Goes to China To Grow Pipeline in up to $881M TransThera Deal
November 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
Neuroscience
Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold
November 3, 2025
 · 
1 min read
 · 
Annalee Armstrong